Literature DB >> 27408369

Systemic Mastocytosis with Associated Clonal Hematological Non-Mast Cell Lineage Disorder (MDS-RCMD): A Difficult Disease to Diagnose and Treat.

Sriram Ravichandran1, Rohith G Chitrapur1, Saurabh Bhave1, Anupam Chakrapani1, Reena Nair1, Mammen Chandy1.   

Abstract

Systemic mastocytosis is a rare and recalcitrant disorder with nonspecific clinical features. Hence, a high index of suspicion is required. Here, we report the case of a 64 years old male presenting with chronic diarrhoea that was evaluated at different centres and treated with multiple lines of therapy. The diagnosis of aggressive systemic mastocytosis was finally clinched following a holistic work up that included a Jejunal biopsy and a laparoscopic lymph node biopsy. Treatment of this disorder is difficult, responses are transient and most patients will eventually relapse, as illustrated by this case. Cladribine, Interferon α, steroids and imatinib have limited success in the management of this disease. The role of stem cell transplant is uncertain.

Entities:  

Keywords:  Cladribine; Mast cell disorders; Systemic mastocytosis

Year:  2015        PMID: 27408369      PMCID: PMC4925525          DOI: 10.1007/s12288-015-0594-2

Source DB:  PubMed          Journal:  Indian J Hematol Blood Transfus        ISSN: 0971-4502            Impact factor:   0.900


  6 in total

1.  Response to interferon alfa-2b in a patient with systemic mastocytosis.

Authors:  H C Kluin-Nelemans; J H Jansen; H Breukelman; B G Wolthers; P M Kluin; H M Kroon; R Willemze
Journal:  N Engl J Med       Date:  1992-02-27       Impact factor: 91.245

2.  Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors.

Authors:  Ken-Hong Lim; Ayalew Tefferi; Terra L Lasho; Christy Finke; Mrinal Patnaik; Joseph H Butterfield; Rebecca F McClure; Chin-Yang Li; Animesh Pardanani
Journal:  Blood       Date:  2009-04-10       Impact factor: 22.113

3.  A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis.

Authors:  R Nakamura; S Chakrabarti; C Akin; J Robyn; E Bahceci; A Greene; R Childs; C E Dunbar; D D Metcalfe; A J Barrett
Journal:  Bone Marrow Transplant       Date:  2006-02       Impact factor: 5.483

Review 4.  Response to therapy with interferon alpha-2b and prednisolone in aggressive systemic mastocytosis: report of five cases and review of the literature.

Authors:  Alexander W Hauswirth; Ingrid Simonitsch-Klupp; Martin Uffmann; Elisabeth Koller; Wolfgang R Sperr; Klaus Lechner; Peter Valent
Journal:  Leuk Res       Date:  2004-03       Impact factor: 3.156

5.  Cladribine therapy for systemic mastocytosis.

Authors:  Hanneke C Kluin-Nelemans; J Marja Oldhoff; Jasper J Van Doormaal; Jan W Van 't Wout; Gregor Verhoef; Wim B J Gerrits; O Aart van Dobbenburgh; Suzanne G Pasmans; Rob Fijnheer
Journal:  Blood       Date:  2003-08-21       Impact factor: 22.113

6.  Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis.

Authors:  Arturo Vega-Ruiz; Jorge E Cortes; Matjaz Sever; Taghi Manshouri; Alfonso Quintás-Cardama; Raja Luthra; Hagop M Kantarjian; Srdan Verstovsek
Journal:  Leuk Res       Date:  2009-02-03       Impact factor: 3.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.